-transparent.png){kind=logo}
The pharmacokinetics of cefpirome (CPR), a new injectable cephem, were studied in 9 patients with various degrees (classified by Ccr.) of impaired renal function. Serum and urinary concentrations of CPR were measured by bioassay. The pharmacokinetic analyses were based on a two compartment open model. As renal impairment increased, higher serum concentrations were maintained in beta-phase and higher urinary concentrations were kept over a long time, as well. As a conclusion, it is necessary to consider the adequate administration and dosage for patients with renal impairment to prevent side effects caused by the maintenance of cefpirome in serum over a long time.
Related Publications
Y Ogata, and
H Suzuki, and
T Saruta
September 1982,
The Journal of antimicrobial chemotherapy,
Y Ogata, and
H Suzuki, and
T Saruta
November 1976,
The Journal of infectious diseases,
Y Ogata, and
H Suzuki, and
T Saruta
January 1988,
Drugs under experimental and clinical research,
Y Ogata, and
H Suzuki, and
T Saruta
April 1993,
Antimicrobial agents and chemotherapy,
Y Ogata, and
H Suzuki, and
T Saruta
October 1986,
The Japanese journal of antibiotics,
Y Ogata, and
H Suzuki, and
T Saruta
January 1990,
Drugs,
Y Ogata, and
H Suzuki, and
T Saruta
January 1986,
European journal of clinical pharmacology,
Y Ogata, and
H Suzuki, and
T Saruta
January 1989,
British journal of clinical pharmacology,
Y Ogata, and
H Suzuki, and
T Saruta
January 1992,
European journal of clinical pharmacology,
Y Ogata, and
H Suzuki, and
T Saruta
July 1992,
Clinical pharmacology and therapeutics,
